(firstQuint)Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly.

 This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-line treatment in elderly subjects ( 70 years old) with advanced non small cell lung cancer who have not received prior chemotherapy for their advanced disease and are not candidates for curative surgery or radiation therapy.

 The primary study endpoint is the percentage of subjects with either peripheral neuropathy or myelosuppression adverse events.

 Patients will continue treatment until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study, according to local standard of care.

 Patients will have radiographic evaluations every 6 weeks while on treatment.

.

 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly@highlight

Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subject ( 70 years old) with advanced NSCLC